Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

Robin L. Jones*, Mark J. Ratain, Peter J. O'Dwyer, Lillian L. Siu, Jacek Jassem, Jacques Medioni, Maja DeJonge, Charles Rudin, Michael Sawyer, David Khayat, Ahmad Awada, Judith M. P. G. M. de Vos-Geelen, T. R. Jeffry Evans, Jennifer Obel, Bruce Brockstein, Jacques DeGreve, Jean-Francois Baurain, Robert Maki, David D'Adamo, Mark DicksonSamir Undevia, David Geary, Linda Janisch, Philippe L. Bedard, Albiruni R. Abdul Razak, Rebecca Kristeleit, Joanna Vitfell-Rasmussen, Ian Walters, Stan B. Kaye, Gary Schwartz

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)132-139
Number of pages8
JournalEuropean Journal of Cancer
Volume120
DOIs
Publication statusPublished - Oct 2019

Keywords

  • Brivanib
  • Solid tumours
  • Randomised discontinuation trial
  • FGF2 status
  • Sarcomas
  • Ovarian cancer
  • GROWTH-FACTOR RECEPTOR-2
  • SOFT-TISSUE SARCOMA
  • INHIBITOR
  • PAZOPANIB

Cite this